MacroGenics, Inc. (MGNX) EPS Estimated At $-1.08

April 26, 2018 - By Stephen Andrade

Investors sentiment decreased to 1.11 in 2017 Q4. Its down 0.47, from 1.58 in 2017Q3. It is negative, as 14 investors sold MacroGenics, Inc. shares while 31 reduced holdings. 15 funds opened positions while 35 raised stakes. 28.26 million shares or 1.97% more from 27.72 million shares in 2017Q3 were reported.
Employees Retirement Sys Of Ohio has 47,715 shares for 0% of their portfolio. Us Savings Bank De invested in 0% or 572 shares. Private Cap Advsr Inc has invested 0.12% in MacroGenics, Inc. (NASDAQ:MGNX). Dafna Cap Mngmt Limited Co owns 1.58% invested in MacroGenics, Inc. (NASDAQ:MGNX) for 154,200 shares. 100 were accumulated by Perigon Wealth Mngmt Limited Liability. Parallax Volatility Advisers Ltd Partnership holds 0% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX) for 5,166 shares. Royal National Bank & Trust Of Canada holds 0% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX) for 3,211 shares. Pennsylvania-based Federated Investors Inc Pa has invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). Legal & General Group Incorporated Public Ltd Liability Company has invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). Muhlenkamp And Inc holds 0.06% in MacroGenics, Inc. (NASDAQ:MGNX) or 10,515 shares. Utd Services Automobile Association holds 0% or 36,000 shares. Moreover, Commercial Bank Of Ny Mellon Corporation has 0% invested in MacroGenics, Inc. (NASDAQ:MGNX). Ubs Asset Management Americas has 0.01% invested in MacroGenics, Inc. (NASDAQ:MGNX). Vident Invest Advisory Limited Liability has invested 0.06% in MacroGenics, Inc. (NASDAQ:MGNX). Baker Bros Advsr L P has 363,676 shares.

Since January 16, 2018, it had 0 insider purchases, and 7 insider sales for $1.10 million activity. 23,967 shares were sold by Cilinski Lynn, worth $599,436 on Wednesday, February 28. Shares for $155,000 were sold by Karrels James on Monday, March 5. Wigginton Jon Marc sold $100,000 worth of stock or 5,000 shares.

Analysts expect MacroGenics, Inc. (NASDAQ:MGNX) to report $-1.08 EPS on May, 2.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-1.08 EPS. After having $2.80 EPS previously, MacroGenics, Inc.’s analysts see -138.57 % EPS growth. The stock increased 0.30% or $0.07 during the last trading session, reaching $23.11. About 3,461 shares traded. MacroGenics, Inc. (NASDAQ:MGNX) has risen 31.18% since April 26, 2017 and is uptrending. It has outperformed by 19.63% the S&P500.

MacroGenics, Inc. (NASDAQ:MGNX) Ratings Coverage

Among 7 analysts covering Macrogenics (NASDAQ:MGNX), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Macrogenics had 7 analyst reports since November 10, 2017 according to SRatingsIntel. Citigroup maintained the stock with “Neutral” rating in Friday, November 10 report. Morgan Stanley maintained it with “Equal-Weight” rating and $26 target in Wednesday, March 14 report. SunTrust maintained MacroGenics, Inc. (NASDAQ:MGNX) on Tuesday, January 23 with “Buy” rating. BTIG Research maintained the shares of MGNX in report on Friday, January 19 with “Buy” rating. The firm earned “Buy” rating on Friday, April 6 by Leerink Swann.

MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company has market cap of $975.19 million. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It currently has negative earnings. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate.

MacroGenics, Inc. (NASDAQ:MGNX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.